I'd be happy to take that! Doubling my position 😬😬

Cellebrite DI
Price
Discussion sur CLBT
Postes
13A Small Restock
Is the market reaction overblown? Yes!
Should we see this as an opportunity? Yes!
Should we buy? Definitely 🫡
Cellebrite Announces Leadership Change and Forecast Revision
Here's the hot stuff from the Cellebrite DI $CLBT (-1,37 %)
(NASDAQ: CLBT) Q2 2026 Earnings Release, fresh off the press:
🚀 Top-line Growth & ARR Dip
Cellebrite posted gains in revenue and profitability in the second quarter but fell slightly short of its own ARR target:
Revenue (Topline): Climbed by +16% to $131.1 million (within the guidance range of $130–133 million).
Annual Recurring Revenue (ARR): Rise to $507.8 million (+21% YoY). This put ARR just below the company’s own guidance range of $510–513 million.
Reason for the shortfall: Management cites longer sales cycles (longer sales cycles) as well as a slightly slower conversion rate for the new Inseyetsmigration.
🔮 Profitability beats estimates & margins are strong
Despite the slight slowdown in recurring revenue, operating leverage continues to improve margins:
Non-GAAP EPS: Stood at $0.11 per share , exceeding the analyst consensus ($0.07) by +$0.04.
Adjusted EBITDA: Reached $31.8 million (a solid margin of 24.2% vs. expected 22–23%).
GAAP Net Income: Amounted to $6.4 million (Non-GAAP net income: $29.7 million).
🤖 Leadership Change & Adjustment to Full-Year Forecast
High-Profile CEO Change:
Shiven Ramji (formerly President of Products & Technology) takes over as CEO from Thomas E. Hogan!
2026 Forecast Adjustment:
ARR adjustment: Annual target slightly lowered to $550 million to $560 million (previously $567–573 million, corresponding to approximately +14% to +16% growth).
Revenue Adjustment: Slightly adjusted to $555 million to $561 million (previously $565–571 million).
EBITDA increase: The full-year adjusted EBITDA target, however, was raised to $153 million to $159 million (previously $149–155 million)!
⚡ 💡 Jack’s take
A double-edged sword that could cause share price volatility in the short term: Operationally, Cellebrite is earning more money than Wall Street expected (an EPS beat of +4 cents) thanks to rock-solid EBITDA margins (24.2%). The downside lies in the ARR falling slightly short of expectations and the reduced annual revenue guidance due to longer deal cycles. However, the fact that Shiven Ramji—the former head of products—is stepping up to the top spot and that the EBITDA target for 2026 has been raised shows that the profitability machine is rock-solid!
Cellebrite Announces Leadership Change and Forecast Revision
Here's the hot stuff from the Cellebrite DI $CLBT (-1,37 %)
(NASDAQ: CLBT) Q2 2026 Earnings Release, fresh off the press:
🚀 Top-line Growth & ARR Dip
Cellebrite posted gains in revenue and profitability in the second quarter but fell slightly short of its own ARR target:
Revenue (Topline): Climbed by +16% to $131.1 million (within the guidance range of $130–133 million).
Annual Recurring Revenue (ARR): Rise to $507.8 million (+21% YoY). This put ARR just below the company’s own guidance range of $510–513 million.
Reason for the shortfall: Management cites longer sales cycles (longer sales cycles) as well as a slightly slower conversion rate for the new Inseyetsmigration.
🔮 Profitability beats estimates & margins are strong
Despite the slight slowdown in recurring revenue, operating leverage continues to improve margins:
Non-GAAP EPS: Stood at $0.11 per share , exceeding the analyst consensus ($0.07) by +$0.04.
Adjusted EBITDA: Reached $31.8 million (a solid margin of 24.2% vs. expected 22–23%).
GAAP Net Income: Amounted to $6.4 million (Non-GAAP net income: $29.7 million).
🤖 Leadership Change & Adjustment to Full-Year Forecast
High-Profile CEO Change:
Shiven Ramji (formerly President of Products & Technology) takes over as CEO from Thomas E. Hogan!
2026 Forecast Adjustment:
ARR adjustment: Annual target slightly lowered to $550 million to $560 million (previously $567–573 million, corresponding to approximately +14% to +16% growth).
Revenue Adjustment: Slightly adjusted to $555 million to $561 million (previously $565–571 million).
EBITDA increase: The full-year adjusted EBITDA target, however, was raised to $153 million to $159 million (previously $149–155 million)!
⚡ 💡 Jack’s take
A double-edged sword that could cause share price volatility in the short term: Operationally, Cellebrite is earning more money than Wall Street expected (an EPS beat of +4 cents) thanks to rock-solid EBITDA margins (24.2%). The downside lies in the ARR falling slightly short of expectations and the reduced annual revenue guidance due to longer deal cycles. However, the fact that Shiven Ramji—the former head of products—is stepping up to the top spot and that the EBITDA target for 2026 has been raised shows that the profitability machine is rock-solid!
Cellebrite Launches the New Age of Investigations with Genesis, Now Generally Available
TYSONS CORNER, Va. and PETAH TIKVA, Israel, June 10, 2026 /PRNewswire/ -- Cellebrite DI Ltd. $CLBT (-1,37 %) (Nasdaq: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced Cellebrite Genesis general availability. Genesis allows investigators faced with increasing crime and data types to quickly and intuitively interrogate digital evidence using the product's agentic AI capabilities to surface intelligence in minutes rather than days or weeks.
@Get_Rich_or_Die_Tryin fühl dich angepingt (geht irgendwie nicht) warum gibst du deinem Kult keine News 👋🤣
What's New at General Availability
The general availability release expands Genesis with capabilities shaped directly by Early Access customer feedback:
- Warrant-Bound Search. Investigators can set Genesis to search only within the parameters of their search warrant, so the AI stays inside what the law allows on every case.
- Location Intelligence. A new map view shows where people and events moved across a case, making patterns easier to spot.
- Upgraded Media Analysis. Smarter analysis of images, video and audio, including transcription and translation of approximately 120 languages, showing who said what, line by line.
- Refined Agentic Accuracy. The AI is better at knowing what it can and cannot do and relaying that to the user which ultimately means cleaner discoveries, answers and tighter connections back to the source evidence.
"Genesis was built on the belief that evidence should move at the speed of the case. When the people closest to an investigation can act sooner, justice moves faster, and communities, nations and businesses are better protected," said Shiven Ramji, president, products and technology, Cellebrite. "General availability means agencies of any size can now operationalize agentic AI on real casework with capability that fortifies the chain of custody, delivers source traceability and is grounded in the operational discipline that public safety demands."
Source: investors.cellebrite.com
Erstkauf Cellebrite DI
Good morning,
I added the first tranche to my portfolio yesterday evening. $CLBT (-1,37 %) into the portfolio last night. Target size 250 shares.
LG and have a nice weekend
John
Cellebrite DI - SL triggered
After only a few days of holding the shares, we had to $CLBT (-1,37 %) had to leave the depot yesterday.
Month in review May 2026
May was a good month with a return of +6.24%.
The YTD is with +6% finally back in the green. 📈
The winners in May are:
$RKLB (-1,75 %) with a plus of almost 83% 📈
$IREN (+0,27 %) with a plus of over 46% 📈
$ONDS (-1,03 %) with an increase of over 40% 📈
Losers in May are:
$PNG (-0,13 %) with a minus of over 2% 📉
$MDB (-0,53 %) with a minus of almost 2% 📉
$ASML (+0,15 %) with a minus of almost 2% 📉
New stocks found their way into the portfolio:
$MDB (-0,53 %) , $ASML (+0,15 %) , $SU (+0,39 %) , $VSTM (-0,56 %)
$CLBT (-1,37 %)
Other values had to give way:
$LMND (-0,44 %) , $OHB (-2,58 %) , $ZTS (-0,06 %) , $TEM (-0,04 %) , $DR0 (+2,98 %) , $MSFT (-0,71 %)
A realignment of my strategy is planned from next month. The aim is to build up a core. This is currently still at a portfolio size of just under 54%. $4GLD (+0,14 %) . This is to be left behind, instead the $ (-0,05 %)VWRL (-0,05 %) is to be saved with €20 per day.
In addition, I started my small AI project Velocity. More details on this in the last post.
First purchase 😂
Thank you @Get_Rich_or_Die_Tryin & @Aktienhauptmeister for presenting this pearl to us 🙏🏽
FOMO has definitely hooked me, that's why I decided to join here 😁
let's see where the journey goes 👀🚀
CLBT 🔒📱🕵🏼♂️ now in the depot
The money freed up by the triggered SL of $OHB (-2,58 %) has now been partly invested in a new security that I did not know about until yesterday.
Thank you @Get_Rich_or_Die_Tryin for the great presentation!
Titres populaires
Meilleurs créateurs cette semaine

